New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
14:55 EDTALXNAlexion informed Health Ministers will not follow AGNSS Soliris recommendation
Alexion Pharma UK, a subsidiary of Alexion Pharmaceuticals, announced it has been informed by the National Specialised Commissioning Team that the Ministers of Health have decided to not follow a positive recommendation by the Advisory Group for National Specialised Services, or AGNSS, when assessing Soliris as a treatment for patients with atypical haemolytic uraemic syndrome. The Ministers of Health have overruled this expert committee recommendation and instead referred consideration of Soliris for the treatment of patients with aHUS to the National Institute for Health and Clinical Excellence. Alexion said it is committed to working with the Health Ministers to make Soliris available to children and adults as quickly as possible, and calls upon the Ministers to accept the recommendation of the significant number of experts and lay people called upon to review Soliris without delay, and to reverse his decision and accept the recommendation of AGNSS in the best interests of aHUS patients in England. Alexion said, "It is important to underscore that the UK Government developed a specific process and authorised a committee, AGNSS, to evaluate treatments addressing patients with very rare disorders, and that AGNSS concluded that 'eculizumab should be routinely nationally commissioned for patients with aHUS.'"
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
08:33 EDTALXNAlexion has reached attractive entry point, says SunTrust
Subscribe for More Information
April 23, 2015
11:23 EDTALXNAlexion weakness a buying opportunity, says Cowen
06:41 EDTALXNAlexion backs FY15 non-GAAP EPS view $5.60-$5.80, consensus $5.87
Subscribe for More Information
06:39 EDTALXNAlexion reports Q1 non-GAAP EPS $1.28, consensus $1.33
Reports Q1 revenue $600.3M, consensus $591.38M. Reports Q1 net product sales of Soliris $600.3M vs. $566.6M a year ago.
April 22, 2015
15:50 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information
April 20, 2015
07:18 EDTALXNAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use